The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions
Open accessAbstract
Cancer's staggering molecular heterogeneity demands innovative approaches beyond traditional single-omics methods. The integration of multi-omics data, spanning genomics, transcriptomics, proteomics, metabolomics and radiomics, can improve diagnostic and prognostic accuracy when accompanied by rigorous preprocessing and external validation; for example, recent integrated classifiers report AUCs around 0.81-0.87 for difficult early-detection tasks. This review synthesizes how artificial intelligence (AI), particularly deep learning and machine learning, bridges this gap by enabling scalable, non-linear integration of disparate omics layers into clinically actionable insights. We explore cutting-edge AI methodologies, including graph neural networks for biological network modeling, transformers for cross-modal fusion, and explainable AI (XAI) for transparent clinical decision support. Critical applications are highlighted, such as AI-driven therapy selection (e.g., predicting targeted therapy resistance), proteogenomic early detection, and radiogenomic non-invasive diagnostics. We further address translational challenges: data harmonization, batch correction, missing data imputation, and computational scalability. Emerging trends, federated learning for privacy-preserving collaboration, spatial/single-cell omics for microenvironment decoding, quantum computing, and patient-centric "N-of-1" models, signal a paradigm shift toward dynamic, personalized cancer management. Despite persistent hurdles in model generalizability, ethical equity, and regulatory alignment, AI-powered multi-omics integration promises to transform precision oncology from reactive population-based approaches to proactive, individualized care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Integrated multi-omics classifiers consistently outperform single-modality models, with recent analyses reporting AUCs of 0.81–0.87 for early cancer detection using cross-omics feature integration”
From A generative AI multi-agent framework with integrated XAI governance for cancer diagnostics: from multi-omics interpretation to lifestyle risk stratification (2026) · cites this paper as Hsu et al., 2026
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Cancer Genome Atlas provides the most accessible resource for MO-XAI Agent validation, with comprehensive genomic and transcriptomic data for 33 cancer types linked to clinical outcomes (Hsu et al., 2026).”
From A generative AI multi-agent framework with integrated XAI governance for cancer diagnostics: from multi-omics interpretation to lifestyle risk stratification (2026) · cites this paper as Hsu et al., 2026
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FAIR Guiding Principles for scientific data management and stewardship
Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.-W., da Silva Santos, L. B., Bourne, P. E., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.18 · Cited by 18,423 · cited 2×
“…directly affect whether AI-multiomics systems reach patients: (a) Interoperability & provenance: Use machine-readable metadata and standard schemas (FAIR; HL7 FHIR Genomics profiles) plus immu - table provenance logs so that data lineage and pre-analytical differences are auditable [ 61 , 62 ].”
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658 · cited 1×
“…(e.g., proteomics vs. tran - scriptomics, spatial vs. bulk), consider domain-adversarial encoders or conditional VAEs for domain-invariant repre - sentation learning, but also quantify residual batch signal (e.g., silhouette score by batch, variance explained by batch pre/post) [ 47 , 48].”
ComBat-seq: batch effect adjustment for RNA-seq count data
Zhang, Y., Parmigiani, G., & Johnson, W. E. (2020) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaa078 · Cited by 1,566 · cited 1×
“…(e.g., proteomics vs. tran - scriptomics, spatial vs. bulk), consider domain-adversarial encoders or conditional VAEs for domain-invariant repre - sentation learning, but also quantify residual batch signal (e.g., silhouette score by batch, variance explained by batch pre/post) [ 47 , 48].”
Deep learning-based multi-omics integration robustly predicts survival in liver cancer
Chaudhary, K., Poirion, O. B., Lu, L., & Garmire, L. X. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0853 · Cited by 1,091 · cited 1×
“…and provide candidate biomarkers, but they do not by themselves prove clinical utility, prospective interventional testing is still required [ 52]. steps, the federated model update schedule, and privacy-preserving mechanisms (e.g., differential privacy budget, homomorphic encryption)…”
Marrero, J. A., Feng, Z., Wang, Y., Nguyen, M. H., Befeler, A. S., Roberts, L. R., Reddy, K. R., Harnois, D., Llovet, J. M., Normolle, D., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.005 · Cited by 745 · cited 2×
“Recent HCC reviews and meta-analyses highlight the het - erogeneity of treatment response and the need for immune-aware stratification when selecting second-line therapies [ 51].”
Wang, T., Shao, W., Huang, Z., Tang, H., Zhang, J., Ding, Z., & Huang, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23774-w · Cited by 671 · cited 3×
“…cohort studies, models like moGAT use atten - tion mechanisms to weight features from genomic, epig - enomic, and transcriptomic graphs, achieving an AUC of 0.92 in classifying cancer subtypes by effectively capturing the topological dependencies between molecular features [30, 32 , 33 ].”
InfluentialGenomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Rodon, J., Soria, J.-C., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 578 · cited 2×
“…should state (a) whether the model produced an actionable recommendation or was used only for stratification, (b) the prospective endpoint (e.g., ORR, PFS ratio, OS), (c) whether the decision was autonomous or MTB-mediated, and (d) performance on pre - specified fairness/subgroup metrics [ 53].”
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine
He, X., Liu, X., Zuo, F., Shi, H., & Jing, J. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.009 · Cited by 445 · cited 6×
“Similarly, integrated omics classifiers have demonstrated robust diagnostic capabilities (AUC 0.81–0.87) for malignancies such as pancreatic can - cer where early detection remains challenging [ 17 , 22 ].”
InfluentialNavigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare
Mohr, A. E., Ortega-Santos, C. P., Whisner, C. M., Klein-Seetharaman, J., & Jasbi, P. (2024) · Biomedicines · doi:10.3390/biomedicines12071496 · Cited by 311 · cited 5×
“Recent implementa - tions leverage GNNs to model molecular interactions within tumor ecosystems, creating in silico simulations that predict individual responses to combination therapies [ 6 , 43].”
InfluentialDeep learning-based approaches for multi-omics data integration and analysis
Ballard, J. L., Wang, Z., Li, W., Shen, L., & Long, Q. (2024) · BioData Mining · doi:10.1186/s13040-024-00391-z · Cited by 258 · cited 6×
“The major trade-off for this enhanced power is their hunger for large sample sizes and substantial com - putational resources, making them prone to overfitting on rare cancer datasets without careful regularization [ 27 , 31].”
Influential
Research works printed but not linked: 10
- Camps J, et al. Artificial intelligence-driven integration of multi-omics and radiomics: A new hope for precision cancer diagnosis and prognosis. Biochim Biophys Acta Mol Basis Dis. 2025;1871(6):167841. · DOI
- Shmmon, Ahmad (2024) The Role of Artificial Intelligence in Diagnosing Malignant Tumors Eurasian Journal of Medicine and Oncology 281-294 10.14744/ejmo.2024.24486 · DOI
- Cai Z et al. Transformer-based deep learning integrates multi-omic data with cancer pathways. bioRxiv, 2024: p. 2022.10.27.514141. · DOI · Paper page
- Mohr AE, et al. Navigating challenges and opportunities in Multi-Omics integration for personalized healthcare. Biomedicines. 2024;12(7):1496. · DOI · Paper page
- Sartori F et al. A comprehensive review of deep learning applications with Multi-Omics data in cancer research. Genes (Basel), 2025. 16(6). · DOI
- Shao Y, et al. Artificial Intelligence-Driven precision medicine: Multi-Omics and Spatial Multi-Omics approaches in diffuse large B-Cell lymphoma (DLBCL). Front Biosci (Landmark Ed). 2024;29(12):404. · DOI
- Mattei P-A, Frellsen J. MIWAE: Deep Generative Modelling and Imputation of Incomplete Data Sets. in International Conference on Machine Learning. 2019.
- Palmer DC, et al. GEMINI-NSCLC study: integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2025;43(16suppl):TPS8114–8114.
- Srivastava R. Advancing precision oncology with AI-powered genomic analysis. Front Pharmacol. 2025;16:1591696. · DOI
- Ferber D, et al. Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology. Nat Cancer. 2025;6(8):1337–49. · DOI · Paper page
Cited by
AbdelHamid, S. G., Halawa, E. M., Ibrahim, E., & ElHefnawi, M. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04263-w · Cited by 25
Fawzy, M. P., Nafie, M. S., Nabih, N. W., Diab, M. K., Babker, A. M. A., Mohamed, H., Hassan, H. A. F. M., & Fahmy, S. A. (2026) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2026.100168 · Cited by 17
Darzi, A., Shokouhfar, M., Farajee, N., Ghafari, A., Deldar, F., Eini, P., Vanan, A. G., & Bahrami, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118875 · Cited by 15
Deep Learning-Enabled Multi-Omics Integration: A New Frontier in Precise Drug Target Discovery
Ren, Y., Bai, H., Wang, J., Yang, Y., & Wang, Y. (2026) · Biology · doi:10.3390/biology15050410 · Cited by 18
“To bridge this divide, the field must pivot from correlation-based learning toward causality-aware XAI frameworks [140,141].”
Omics medicine: what the clinicians should know
Zamperla, M. G., Barbi, V., Negri, S., Atlante, S., & Gaetano, C. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106759 · Cited by 14
Metadata
- Authors
- Hsu, C.-Y., Askar, S., Alshkarchy, S. S., Nayak, P. P., Attabi, K. A. L., Khan, M. A., Mayan, J. A., Sharma, M. K., Islomov, S., & Soleimani Samarkhazan, H.
- Affiliations
- Chia Nan University of Pharmacy and Science (TW)
- Erbil Polytechnic University (IQ)
- Al-Qasim Green University (IQ)
- Siksha O Anusandhan University (IN)
- Islamic University of Najaf (IQ)
- Dhofar University (OM)
- Sathyabama Institute of Science and Technology (IN)
- Chaudhary Charan Singh University (IN)
- ORCID
- Venue
- Clinical and Experimental Medicine
- Published
- 2025-11-21
- Volume
- 26
- Issue
- 1
- Pages
- 29-29
- ISSN
- 1591-8890 (ISSN-L)
- 1591-9528
- PMC
- PMC12634751
- OpenAlex
- W4416442660
- Cited by
- 140
- References
- 74
- Citations by year
- 2026: 136 · 2025: 4
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Clinical and Experimental Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- multi-omics integration, precision oncology, artificial intelligence in oncology, deep learning, graph neural networks, transformer models, cross-modal fusion, explainable AI, clinical decision support, radiogenomics, non-invasive cancer diagnosis, data harmonization, batch effect correction, missing data imputation, federated learning, single-cell omics, tumor microenvironment, quantum computing, model generalization
- MeSH terms
- Clinical Decision-Making, Machine Learning, Deep Learning, Multiomics, Artificial Intelligence, Humans, Medical Oncology, Neoplasms, Genomics, Proteomics, Metabolomics, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. https://app.cochat.ai/papers/10.1007/s10238-025-01965-9
- The paper
- Hsu, C.-Y., Askar, S., Alshkarchy, S. S., Nayak, P. P., Attabi, K. A. L., Khan, M. A., Mayan, J. A., Sharma, M. K., Islomov, S., & Soleimani Samarkhazan, H. (2025). AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01965-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.